Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonesitatug Vedotin Combinations in 1L CLDN18.2+, HER2- Gastric, GEJ, or Esophageal Adenocarcinoma
NCT07431281Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Primary completion
- Aug 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 24
01
Overview
Phase 3, randomised trial of sonesitatug vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma and esophageal cancer (5 arms), sponsored by AstraZeneca. Primary endpoints: Progression Free Survival at 5 years and Overall Survival at 5 years. Started Feb 2026; status: recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal cancer
Beyond the preview
Go deeper on NCT07431281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431281.